

INIM0031: Neoplasia and its Treatment

[View Online](#)

[1]

Ajila, V. et al. 2015. Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. *Journal of Sexually Transmitted Diseases*. 2015, (2015), 1-5.
DOI:<https://doi.org/10.1155/2015/791024>.

[2]

Barrett, D.M. et al. 2015. Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. *The Journal of Immunology*. 195, 3 (Aug. 2015), 755-761.
DOI:<https://doi.org/10.4049/jimmunol.1500751>.

[3]

Ecker, D.M. et al. 2015. The therapeutic monoclonal antibody market. *mAbs*. 7, 1 (Jan. 2015), 9-14. DOI:<https://doi.org/10.4161/19420862.2015.989042>.

[4]

Gill, S. and June, C.H. 2015. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. *Immunological Reviews*. 263, 1 (Jan. 2015), 68-89.
DOI:<https://doi.org/10.1111/imr.12243>.

[5]

Grupp, S.A. et al. 2013. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. *New England Journal of Medicine*. 368, 16 (Apr. 2013), 1509-1518.
DOI:<https://doi.org/10.1056/NEJMoa1215134>.

[6]

Hanahan, D. and Weinberg, R.A. 2000. The Hallmarks of Cancer. *Cell*. 100, 1 (Jan. 2000), 57–70. DOI:[https://doi.org/10.1016/S0092-8674\(00\)81683-9](https://doi.org/10.1016/S0092-8674(00)81683-9).

[7]

zur Hausen, H. 2009. Papillomaviruses in the causation of human cancers — a brief historical account. *Virology*. 384, 2 (Feb. 2009), 260–265. DOI:<https://doi.org/10.1016/j.virol.2008.11.046>.

[8]

Hodi, F.S. et al. 2010. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. *New England Journal of Medicine*. 363, 8 (Aug. 2010), 711–723. DOI:<https://doi.org/10.1056/NEJMoa1003466>.

[9]

Jeggo, P.A. et al. 2015. DNA repair, genome stability and cancer: a historical perspective. *Nature Reviews Cancer*. 16, 1 (Dec. 2015), 35–42. DOI:<https://doi.org/10.1038/nrc.2015.4>.

[10]

Kaufman, H.L. et al. 2015. Oncolytic viruses: a new class of immunotherapy drugs. *Nature Reviews Drug Discovery*. 14, 9 (Sep. 2015), 642–662. DOI:<https://doi.org/10.1038/nrd4663>.

[11]

Klebanoff, C.A. et al. 2016. Prospects for gene-engineered T cell immunotherapy for solid cancers. *Nature Medicine*. 22, 1 (Jan. 2016), 26–36. DOI:<https://doi.org/10.1038/nm.4015>.

[12]

Koebel, C.M. et al. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. *Nature*. 450, 7171 (Dec. 2007), 903–907. DOI:<https://doi.org/10.1038/nature06309>.

[13]

Larson, C. et al. 2015. Going viral: a review of replication-selective oncolytic adenoviruses. *Oncotarget*. 6, 24 (Aug. 2015). DOI:<https://doi.org/10.18632/oncotarget.5116>.

[14]

Lazebnik, Y. 2010. What are the hallmarks of cancer? *Nature Reviews Cancer*. 10, 4 (Apr. 2010), 232–233. DOI:<https://doi.org/10.1038/nrc2827>.

[15]

Lingyun Geng 2015. Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. *International Journal of Clinical and Experimental Medicine*. 8, 9 (2015).

[16]

de Martel, C. et al. 2012. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *The Lancet Oncology*. 13, 6 (Jun. 2012), 607–615. DOI:[https://doi.org/10.1016/S1470-2045\(12\)70137-7](https://doi.org/10.1016/S1470-2045(12)70137-7).

[17]

Matsuoka, M. and Jeang, K.-T. 2011. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. *Oncogene*. 30, 12 (Mar. 2011), 1379–1389. DOI:<https://doi.org/10.1038/onc.2010.537>.

[18]

Morris, E.C. and Stauss, H.J. 2016. Optimizing T-cell receptor gene therapy for hematologic malignancies. *Blood*. 127, 26 (Jun. 2016), 3305–3311. DOI:<https://doi.org/10.1182/blood-2015-11-629071>.

[19]

Palucka, K. and Banchereau, J. 2012. Cancer immunotherapy via dendritic cells. *Nature Reviews Cancer*. 12, 4 (Mar. 2012), 265–277. DOI:<https://doi.org/10.1038/nrc3258>.

[20]

Pierangeli, A. et al. 2015. Immunodeficiency-associated viral oncogenesis. *Clinical Microbiology and Infection*. 21, 11 (Nov. 2015), 975–983.
DOI:<https://doi.org/10.1016/j.cmi.2015.07.009>.

[21]

Reichert, J.M. 2016. Antibodies to watch in 2016. *mAbs*. 8, 2 (Feb. 2016), 197–204.
DOI:<https://doi.org/10.1080/19420862.2015.1125583>.

[22]

Reichert, J.M. 2017. Antibodies to watch in 2017. *mAbs*. 9, 2 (Feb. 2017), 167–181.
DOI:<https://doi.org/10.1080/19420862.2016.1269580>.

[23]

Reichert, J.M. 2012. Marketed therapeutic antibodies compendium. *mAbs*. 4, 3 (May 2012), 413–415. DOI:<https://doi.org/10.4161/mabs.19931>.

[24]

Restifo, N.P. et al. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. *Nature Reviews Immunology*. 12, 4 (Mar. 2012), 269–281.
DOI:<https://doi.org/10.1038/nri3191>.

[25]

Robbins, P.F. et al. 2011. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. *Journal of Clinical Oncology*. 29, 7 (Mar. 2011), 917–924.
DOI:<https://doi.org/10.1200/JCO.2010.32.2537>.

[26]

Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth 2011. Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. *Science*. 331, 6024

(2011), 1565–1570.

[27]

Roos, W.P. et al. 2015. DNA damage and the balance between survival and death in cancer biology. *Nature Reviews Cancer*. 16, 1 (Dec. 2015), 20–33. DOI:<https://doi.org/10.1038/nrc.2015.2>.

[28]

Russell, S.J. et al. 2012. Oncolytic virotherapy. *Nature Biotechnology*. 30, 7 (Jul. 2012), 658–670. DOI:<https://doi.org/10.1038/nbt.2287>.

[29]

Schinzari, V. et al. 2015. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. *Clinical Microbiology and Infection*. 21, 11 (Nov. 2015), 969–974. DOI:<https://doi.org/10.1016/j.cmi.2015.06.026>.

[30]

Schumacher, T.N. and Schreiber, R.D. 2015. Neoantigens in cancer immunotherapy. *Science*. 348, 6230 (Apr. 2015), 69–74. DOI:<https://doi.org/10.1126/science.aaa4971>.

[31]

Shankaran, V. et al. 2001. IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. *Nature*. 410, 6832 (Apr. 2001), 1107–1111. DOI:<https://doi.org/10.1038/35074122>.

[32]

Spurgeon, M.E. and Lambert, P.F. 2013. Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. *Virology*. 435, 1 (Jan. 2013), 118–130. DOI:<https://doi.org/10.1016/j.virol.2012.09.029>.

[33]

Topalian, S.L. et al. 2012. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *New England Journal of Medicine*. 366, 26 (Jun. 2012), 2443–2454.
DOI:<https://doi.org/10.1056/NEJMoa1200690>.

[34]

Varghese, S. and Rabkin, S.D. 2002. Oncolytic herpes simplex virus vectors for cancer virotherapy. *Cancer Gene Therapy*. 9, 12 (Dec. 2002), 967–978.
DOI:<https://doi.org/10.1038/sj.cgt.7700537>.

[35]

Weinberg, R.A. 2014. *The biology of cancer*. Garland Science.

[36]

Weiss, R.A. and Vogt, P.K. 2011. 100 years of Rous sarcoma virus. *The Journal of Experimental Medicine*. 208, 12 (Nov. 2011), 2351–2355.
DOI:<https://doi.org/10.1084/jem.20112160>.

[37]

Wendzicki, J.A. et al. 2015. Large T and small T antigens of Merkel cell polyomavirus. *Current Opinion in Virology*. 11, (Apr. 2015), 38–43.
DOI:<https://doi.org/10.1016/j.coviro.2015.01.009>.